A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 120
- Population
- ALL · 40 Years to 60 Years
- Duration
- 2023-02-24 to 2027-01-15
- Intervention
- Ca-AKG
- Comparator
- Placebo
- Outcomes measured
- Change in blood DNA methylation status, years — from baseline to end of intervention (6 months); Complete blood count — from baseline to end of intervention (6 months); Carotid-femoral Pulse Wave Velocity change — from baseline to end of intervention (6 months); Central Blood pressure change — from baseline to end of intervention (6 months); Body Mass Index (BMI) change — from baseline to end of intervention (6 months); Brachial Blood pressure change — from baseline to end of intervention (6 months); Waist/hip ratio change — from baseline to end of intervention (6 months); Bone Mineral Density, g/cm2 change — from baseline to end of intervention (6 months); Fat-free mass, change (kg) — from baseline to end of intervention (6 months); Fat mass, change (kg) — from baseline to end of intervention (6 months); Handgrip strength change (kg) — from baseline to end of intervention (6 months); 8-RM leg extension change (kg) — from baseline to end of intervention (6 months); Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption (V̇O2), L/min — from baseline to end of in…; Cardiopulmonary exercise test (CPET): Change in Volume of Oxygen consumption per kg body weight (V̇O2/kg), L/min/kg — f…; Cardiopulmonary exercise test (CPET): change in lactate — from baseline to end of intervention (6 months); Cardiopulmonary exercise test (CPET): change in heart rate — from baseline to end of intervention (6 months); Cardiopulmonary exercise test (CPET): aerobic and anaerobic threshold change — from baseline to end of intervention (6…; Cardiopulmonary exercise test (CPET): excess post-exercise oxygen consumption change — from baseline to end of interven…; Change in Skin autofluorescence, au — from baseline to end of intervention (6 months); Change in Quality-of-Life questionnaires (SF-36 questionnaires) — from baseline to end of intervention (6 months)
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Alpha-ketoglutarate · 100%Title contains controlled term: alpha-ketoglutarate. Abstract contains controlled term: alpha-ketoglutarate, akg. Source terminology contains: akg. Title supplies longevity context: biological age. Study type is explicitly identified as INTERVENTIONAL.
- Biological age biomarkers · 80%Title contains controlled term: biological age. Title supplies longevity context: biological age. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.